ArticleCalcified tissue international2026
A Large-Scale Multi-omics Polygenic Risk Score Analysis Identified Candidate Biomarkers Associated with Heel Bone Mineral Density.
Article in Calcified tissue international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectivesBone mineral density (BMD) is a critical indicator of osteoporosis (OP). Utilizing the latest multi-omics quantitative trait loci (QTLs) data, we aim to identify novel candidates associated with heel BMD (hBMD).
methodsWe collected QTLs data from the INTERVAL cohort (independent of the UK Biobank (UKB)) that is a randomised trial including approximately 50,000 healthy blood donors enrolled from 25 centres of England's National Health Service Blood and Transplant. We then calculated individual polygenic risk score (PRS) for 13,646 RNAs, 308 proteins (Olink), 2379 proteins (SomaScan), 726 metabolites (Metabolon) and 141 metabolites (Nightingale) in UKB. hBMD was measured by quantitative ultrasound. Generalized linear model was used to evaluate the associations between multi-omics PRS and hBMD in 96,165 subjects. Integrated analysis of multi-omics was performed on the MetaboAnalyst 6.0 platform. Replication analysis was performed using the internal Olink proteomics and Nightingale metabolomics data of UKB. We subsequently explored the causal effects of the targets on hBMD using mendelian randomization (MR) analysis. Significant associations were determined using a false discovery rate (FDR)-adjusted P-value (Padj < 0.05).
resultsWe identified 195 hBMD-associated genes, such as WNT16 (Padj = 6.417 × 10
conclusionOur study not only identified several novel candidate biomarkers such as PLPP3, RGMB, and RNF128 for hBMD but also provided genetic evidence supporting their potential causal roles in bone mineral regulation. These findings could shed light on the molecular underpinnings of OP.
Indexed as
Identifiers
41874668What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.